ESMO: European Society for Medical Oncology

1. Two Health Consortia to Develop a Detailed Feasibility Proposal for Europe’s Next €1-billion Science Projects

   LifeTime and RESTORE among shortlisted projects

2. NICE Develops a Medtech Innovation Briefing on Axumin

   Axumin is a radiopharmaceutical agentfor functional imaging of prostate cancer recurrence

3. Gustave Roussy and Institut Bergonié, Partners for Early Phase Trials and Therapeutic Innovation in Oncology

   Increase in accrual capacity and the quality standards

4. Withdrawal of the EU Marketing Authorisation Applications for Cavoley and Efgratin

   Both contain the active substance pegfilgrastim and were developed as a biosimilar medicine

5. FDA Approved Caplacizumab-yhdp

   Approval is based on results from the HERCULES trial